Nu-Med Plus annual stock-based compensation
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nu-Med Plus Stock-Based Compensation Growth & History (NUMD)
Nu-Med Plus's stock-based compensation was $0 for fiscal 2025.
View full Nu-Med Plus company overviewNu-Med Plus annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | −$41,800 | — |
| 2023 | 2023-12-31 | $41,800 | $6,800 | +19.43% |
| 2022 | 2022-12-31 | $35,000 | −$165,000 | −82.50% |
| 2021 | 2021-12-31 | $200,000 | −$761,150 | −79.19% |
| 2020 | 2020-12-31 | $961,150 | $761,150 | +380.58% |
| 2019 | 2019-12-31 | $200,000 | −$32,061 | −13.82% |
| 2018 | 2018-12-31 | $232,061 | $232,061 | — |
| 2017 | 2017-12-31 | $0 | $0 | — |
| 2016 | 2016-12-31 | $0 | −$409 | — |
| 2015 | 2015-12-31 | $409 | −$10,496 | −96.25% |
| 2014 | 2014-12-31 | $10,905 | $7,721 | +242.49% |
| 2013 | 2013-12-31 | $3,184 | $3,184 | — |
| 2012 | 2012-12-31 | $0 | — | — |
Nu-Med Plus quarterly stock-based compensation
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.23
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2023 | 2023-03-31 | $90.0M | — | — |
| Q4 2016 | 2016-12-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | $0 | — |
| Q2 2016 | 2016-06-30 | $0 | $0 | — |
| Q1 2016 | 2016-03-31 | $0 | −$409 | — |
| Q4 2015 | 2015-12-31 | $0 | −$1,650 | — |
| Q3 2015 | 2015-09-30 | $0 | −$1,996 | — |
| Q2 2015 | 2015-06-30 | $0 | −$3,635 | — |
| Q1 2015 | 2015-03-31 | $409 | −$3,215 | −88.71% |
| Q4 2014 | 2014-12-31 | $1,650 | $231 | +16.28% |
| Q3 2014 | 2014-09-30 | $1,996 | $750 | +60.19% |
| Q2 2014 | 2014-06-30 | $3,635 | $3,116 | +600.39% |
| Q1 2014 | 2014-03-31 | $3,624 | $3,624 | — |
| Q4 2013 | 2013-12-31 | $1,419 | $1,419 | — |
| Q3 2013 | 2013-09-30 | $1,246 | $1,246 | — |
| Q2 2013 | 2013-06-30 | $519 | $519 | — |
| Q1 2013 | 2013-03-31 | $0 | $0 | — |
| Q4 2012 | 2012-12-31 | $0 | −$3,347 | — |
| Q3 2012 | 2012-09-30 | $0 | — | — |
| Q2 2012 | 2012-06-30 | $0 | — | — |
| Q1 2012 | 2012-03-31 | $0 | — | — |
| Q4 2011 | 2011-12-31 | $3,347 | — | — |
Nu-Med Plus stock-based compensation trends
Over the last five fiscal years, Nu-Med Plus's stock-based compensation decreased from $961,150 to $0, a change of −$961,150. The latest reported quarter, Q1 2023, shows $90.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nu-Med Plus source filings ↗